Creative Medical Technology Holdings (CELZ) Operating Expenses (2010 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Operating Expenses of $1.5 million for Q1 2026, down 12.22% year-over-year from $1.7 million in Q1 2025, and down 25.09% quarter-over-quarter from $1.9 million in Q4 2025.
Creative Medical Technology Holdings (CELZ) Operating Expenses (2010 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Operating Expenses for 17 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 12.22% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $5.9 million (down 5.5% YoY), while the FY2025 annual figure was $6.1 million, up 6.89% from the prior year.
- Operating Expenses fell to $1.5 million in Q1 2026 per CELZ's latest filing, from $1.9 million in the prior quarter.
- Across five years, Operating Expenses topped out at $6.3 million in Q4 2022 and bottomed at $1.1 million in Q3 2022.
- Historically, Operating Expenses has averaged $1.7 million across 5 years, with a median of $1.5 million in 2026.
- Annual changes were most pronounced in 2022 — Operating Expenses jumped 319.1% — and 2023, when it tumbled 71.81%.
- Creative Medical Technology Holdings' Operating Expenses stood at $6.3 million in 2022, then sank by 71.81% to $1.8 million in 2023, then advanced by 6.42% to $1.9 million in 2024, then gained by 3.19% to $1.9 million in 2025, then slipped by 25.09% to $1.5 million in 2026.
- Business Quant data shows CELZ's Operating Expenses at $1.5 million in Q1 2026, $1.9 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | 541.02 Mn |
| 10 | Creative Medical Technology Holdings | 1.78 Mn | 1.78 Mn | - | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.56 Mn |
| Mar 31, 2026 | 1.46 Mn |
| Dec 31, 2025 | 1.95 Mn |
| Sep 30, 2025 | 1.27 Mn |
| Jun 30, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.66 Mn |
| Dec 31, 2024 | 1.89 Mn |
| Sep 30, 2024 | 1.11 Mn |
| Jun 30, 2024 | 1.63 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 1.77 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Jun 30, 2023 | 1.19 Mn |
| Mar 31, 2023 | 1.11 Mn |
| Dec 31, 2022 | 6.29 Mn |
| Sep 30, 2022 | 1.06 Mn |
| Jun 30, 2022 | 1.79 Mn |
| Mar 31, 2022 | 1.16 Mn |
| Dec 31, 2021 | 1.50 Mn |
| Sep 30, 2021 | 839,436.00 |